About this page
Insider trades reported on SEC Form 4: when the people who run a company buy or sell its shares with their own money.
How to read it
- Form 4
- The form a company insider (officer, director or owner of more than 10%) must file with the SEC within two business days of buying or selling the company's shares.
- Buy (P) and Sell (S)
- Open-market purchases and sales. Gifts, option exercises and automatic tax withholding are left out because they say little about what the insider thinks.
- Value
- Shares times price, as reported on the filing.
- 10b5-1
- A trade made under a plan set up in advance. Planned sales are common and usually say less than an unplanned purchase.
- Late filing
- A Form 4 filed more than two business days after the trade.
- Vs. S&P 500
- How the stock did after the trade minus how the overall market did in the same weeks.
A real example
In January 2016, when bank stocks were falling, JPMorgan Chase CEO Jamie Dimon bought 500,000 JPMorgan shares with his own money, worth about $26 million. His Form 4 made the purchase public within days, and investors read it as a strong sign of confidence.
Explain it like I'm 13
If the coach of a team bets his own allowance that his team will win, that tells you something. A Form 4 is the note a company boss must hand in whenever he buys or sells his own company's shares, so everyone can see it.
Data from public SEC filings and congressional reports. Information, not investment advice. Check every number against the filing linked on the page.
Adaptive Biotechnologies Corp (ADPT) Insider Trading
43 open-market trades reported since Jun 15, 2026: 0 purchases worth $0 and 43 sales worth $59.5M.
By insider
| Insider | Role | Buys | Bought | Sells | Sold |
|---|---|---|---|---|---|
| Julie Rubinstein | COO | 0 | $0 | 18 | $5.56M |
| Susan Bobulsky | Chief Commercial Officer, MRD | 0 | $0 | 8 | $655K |
| Francis Lo | Chief People Officer | 0 | $0 | 5 | $8.54M |
| Katey Einterz Owen | Director | 0 | $0 | 1 | $250K |
| Robert Hershberg | Director | 0 | $0 | 1 | $748K |
| Chad M. Robins | CEO | 0 | $0 | 2 | $14.9M |
| Peter M. Neupert | Director | 0 | $0 | 1 | $3.14M |
| Harlan S. Robins | Chief Scientific Officer | 0 | $0 | 4 | $21.1M |
| Sharon Benzeno | Chief Commercial Ofc Imm Med | 0 | $0 | 2 | $3.50M |
| Michelle Renee Griffin | Director | 0 | $0 | 1 | $1.05M |
All trades
| Filed | Insider | Type | Value | 3 mo. after |
|---|---|---|---|---|
| Oct 26 | Julie RubinsteinCOO | ▼ SELL10b5-1 | $309K | |
| Oct 26 | Julie RubinsteinCOO | ▼ SELL10b5-1 | $297K | |
| Oct 26 | Julie RubinsteinCOO | ▼ SELL10b5-1 | $291K | |
| Oct 21 | Julie RubinsteinCOO | ▼ SELL10b5-1 | $302K | |
| Oct 21 | Julie RubinsteinCOO | ▼ SELL10b5-1 | $291K | |
| Oct 21 | Julie RubinsteinCOO | ▼ SELL10b5-1 | $286K | |
| Oct 16 | Julie RubinsteinCOO | ▼ SELL10b5-1 | $305K | |
| Oct 16 | Julie RubinsteinCOO | ▼ SELL10b5-1 | $304K | |
| Oct 16 | Julie RubinsteinCOO | ▼ SELL10b5-1 | $288K | |
| Oct 13 | Julie RubinsteinCOO | ▼ SELL10b5-1 | $314K | |
| Oct 13 | Julie RubinsteinCOO | ▼ SELL10b5-1 | $303K | |
| Oct 13 | Julie RubinsteinCOO | ▼ SELL10b5-1 | $303K | |
| Oct 8 | Julie RubinsteinCOO | ▼ SELL10b5-1 | $330K | |
| Oct 8 | Julie RubinsteinCOO | ▼ SELL10b5-1 | $314K | |
| Oct 8 | Julie RubinsteinCOO | ▼ SELL10b5-1 | $305K | |
| Oct 8 | Susan BobulskyChief Commercial Officer, MRD | ▼ SELL10b5-1 | $193K | |
| Oct 5 | Francis LoChief People Officer | ▼ SELL10b5-1 | $758K | |
| Oct 5 | Julie RubinsteinCOO | ▼ SELL10b5-1 | $347K | |
| Oct 5 | Julie RubinsteinCOO | ▼ SELL10b5-1 | $334K | |
| Oct 5 | Julie RubinsteinCOO | ▼ SELL10b5-1 | $333K | |
| Sep 18 | Francis LoChief People Officer | ▼ SELL10b5-1 | $3.24M | |
| Sep 17 | Susan BobulskyChief Commercial Officer, MRD | ▼ SELL10b5-1 | $32K | |
| Aug 28 | Katey Einterz OwenDirector | ▼ SELL | $250K | |
| Aug 20 | Robert HershbergDirector | ▼ SELL | $748K | |
| Aug 19 | Chad M. RobinsCEO | ▼ SELL | $8.06M | |
| Aug 19 | Chad M. RobinsCEO | ▼ SELL | $6.82M | |
| Aug 19 | Peter M. NeupertDirector | ▼ SELL | $3.14M | |
| Aug 12 | Susan BobulskyChief Commercial Officer, MRD | ▼ SELL10b5-1 | $75K | |
| Aug 3 | Susan BobulskyChief Commercial Officer, MRD | ▼ SELL10b5-1 | $31K | |
| Jul 23 | Harlan S. RobinsChief Scientific Officer | ▼ SELL10b5-1 | $10.8M | |
| Jul 20 | Susan BobulskyChief Commercial Officer, MRD | ▼ SELL10b5-1 | $115K | |
| Jul 17 | Francis LoChief People Officer | ▼ SELL10b5-1 | $2.39M | |
| Jul 7 | Harlan S. RobinsChief Scientific Officer | ▼ SELL10b5-1 | $8.50M | |
| Jul 6 | Francis LoChief People Officer | ▼ SELL10b5-1 | $1.14M | |
| Jul 6 | Francis LoChief People Officer | ▼ SELL10b5-1 | $1.01M | |
| Jul 6 | Susan BobulskyChief Commercial Officer, MRD | ▼ SELL10b5-1 | $11K | |
| Jun 30 | Sharon BenzenoChief Commercial Ofc Imm Med | ▼ SELL10b5-1 | $3.27M | |
| Jun 30 | Sharon BenzenoChief Commercial Ofc Imm Med | ▼ SELL10b5-1 | $232K | |
| Jun 29 | Michelle Renee GriffinDirector | ▼ SELL10b5-1 | $1.05M | |
| Jun 29 | Susan BobulskyChief Commercial Officer, MRD | ▼ SELL10b5-1 | $103K | |
| Jun 17 | Harlan S. RobinsChief Scientific Officer | ▼ SELL10b5-1 | $1.74M | |
| Jun 17 | Harlan S. RobinsChief Scientific Officer | ▼ SELL10b5-1 | $111K | |
| Jun 15 | Susan BobulskyChief Commercial Officer, MRD | ▼ SELL10b5-1 | $95K |